Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
Martinez, Pablo (Vall d'Hebron Institut d'Oncologia)
Hernandez-Losa, Javier (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia)
Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
Tallada, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Murtra-Garrell, Nuria (Vall d'Hebron Institut d'Oncologia)
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia)
Rodriguez-Freixinos, Victor (Vall d'Hebron Institut d'Oncologia)
Canela, Mercedes (Vall d'Hebron Institut d'Oncologia)
Ramon y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia)
Universitat Autònoma de Barcelona

Data:	2013
Resum:	Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients. NSCLC patients previously screened for Epidermal Growth Factor Receptor (EGFR) at our institution were selected. ALK positive patients were identified by FISH and the value of IHC (D5F3) was explored. ninety-nine patients were identified. Median age was 61. 5 years (range 35-83), all were caucasians, eighty percent were adenocarcinomas, fifty-one percent were male and thirty-eight percent were current smokers. Seven (7. 1%) patients were ALK positive by FISH, thirteen (13. 1%) were EGFR mutant, and 65 (65. 6%) were negative/Wild Type (WT) for both ALK and EGFR. ALK positivity and EGFR mutations were mutually exclusive. ALK positive patients tend to be younger than EGFR mutated or wt patients. ALK positive patients were predominantly never smokers (71. 4%) and adenocarcinoma (71. 4%). ALK positive and EGFR mutant patients have a better outcome than negative/WT. All patients with ALK FISH negative tumours were negative for ALK IHC. Out of 6 patients positive for ALK FISH with more tissue available, 5 were positive for ALK IHC and 1 negative. ALK positive patients represent 7. 1% of a population of selected NSCLC. ALK positive patients have different clinical features and a better outcome than EGFR WT and ALK negative patients. IHC is a promising method for detecting ALK positive NSCLC patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 8 (january 2013) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0052261
PMID: 23359795

6 p, 348.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats